Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS

被引：0
作者：
Chen Wang
Ting Yang
Jian Kang
Rongchang Chen
Li Zhao
Huijie He
Pryseley N. Assam
Rong Su
Eric Bourne
Shaila Ballal
Kiernan DeAngelis
Paul Dorinsky
机构：
[1] China-Japan Friendship Hospital,Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine
[2] Chinese Academy of Medical Sciences,Institute of Respiratory Medicine
[3] National Clinical Research Center for Respiratory Diseases,Department of Respiratory Medicine
[4] Chinese Academy of Medical Sciences and Peking Union Medical College,The First Affiliated Hospital of Baotou Medical College
[5] Capital Medical University,undefined
[6] The First Hospital of China Medical University,undefined
[7] The First Affiliated Hospital of Guangzhou Medical University,undefined
[8] Shengjing Hospital of China Medical University,undefined
[9] Inner Mongolia University of Science and Technology,undefined
[10] AstraZeneca,undefined
[11] AstraZeneca,undefined
[12] AstraZeneca,undefined
[13] Formerly of AstraZeneca,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Bronchodilator agents; China; Chronic obstructive; Disease exacerbation; Pulmonary disease; Pulmonary function tests;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1591 / 1607
页数：16
相关论文
共 70 条
[1]  
Zhou M(2016)Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 Lancet 387 251-272
[2]  
Wang H(2016)A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the Global Burden of Disease Study 2013 Chest 150 1269-1280
[3]  
Zhu J(2018)Chronic obstructive pulmonary disease in China: a nationwide prevalence study Lancet Respir Med 6 421-430
[4]  
Yin P(2018)Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study Lancet 391 1706-1717
[5]  
Wang H(2017)COPD symptom burden: impact on health care resource utilization, and work and activity impairment Int J Chron Obstruct Pulmon Dis 12 677-689
[6]  
Vos T(2018)Once-daily single-inhaler triple versus dual therapy in patients with COPD N Engl J Med 378 1671-1680
[7]  
Fang L(2018)Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial Lancet Respir Med 6 747-758
[8]  
Gao P(2018)Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial Lancet 391 1076-1084
[9]  
Bao H(2016)Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β Lancet 388 963-973
[10]  
Wang C(1999)-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial Am J Respir Crit Care Med 159 179-187
1234567